| 1. |
Call for global action to reduce childhood asthma deaths |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 2-2
&NA;,
Preview
|
PDF (784KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 2. |
Accelerated drug development delivers results |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 3-4
Kate Palmer,
Preview
|
PDF (1491KB)
|
|
摘要:
Time is most certainly money in the field of drug discovery and development. It takes an average of 10 years to get a drug from the test tube to the market. Therefore, any company that can refine its processes to increase the speed and efficiency of drug development is likely to maximise the return on its investment. Approaches to accelerating the drug development process were discussed at a 1-day seminar organised by the Drug Information Association entitled ‘Taking a Drug Discovery into Pre-Clinical Development’ [Melbourne, Australia; October 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 3. |
Opioid dependencean epidemic that needs to be addressed |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 4-4
&NA;,
Preview
|
PDF (737KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 4. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 5-5
&NA;,
Preview
|
PDF (748KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 5. |
Cost effectiveness of thrombolytics in MInational differences |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 6-6
&NA;,
Preview
|
PDF (732KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 6. |
Olanzapinea step above the rest? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 7-8
Joanne Dalton,
Preview
|
PDF (1545KB)
|
|
摘要:
The economic impact of schizophrenia on healthcare systems is substantial, and it is important to be able to make informed decisions as to which therapies will provide an optimally cost-effective outcome for patients, their care-givers and society at large. The treatment of schizophrenia is in a state of flux, with atypical agents such as Lilly's olanzapine [‘Zyprexa’] and Janssen's risperidone [‘Risperdal’] vying for a significant share of the antipsychotic market. Two studies indicating olanzapine has economic advantages over risperidone and the older conventional antipsychotic agent haloperidol were presented by Lilly researchers at the 11th Congress of the European College of Neurophyschopharmacology [Paris, France; October 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 7. |
Comorbidity bumps up cost of treating GORD patients |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 8-8
&NA;,
Preview
|
PDF (763KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 8. |
RMP-7 plus carboplatinpotential in high-grade glioma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 9-9
&NA;,
Preview
|
PDF (731KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 9. |
Transfer factor improves pain in herpes zoster |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 10-10
&NA;,
Preview
|
PDF (707KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
| 10. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1168,
1998,
Page 11-11
&NA;,
Preview
|
PDF (756KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
首页
